Marshall Wace
SLS icon

Marshall Wace’s SELLAS Life Sciences SLS Stock Holding History

Marshall Wace’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,037,162
Closed -$8.62M – 3688
2026
Q1 		$8.62M Buy
2,037,162
+696,494
+52% +$3.12M 0.01% 1047
2025
Q4 		$5.05M Sell
1,340,668
-1,017,331
-43% -$1.98M ﹤0.01% 1152
2025
Q3 		$3.8M Sell
2,357,999
-357,490
-13% -$637K ﹤0.01% 1305
2025
Q2 		$5.95M Buy
2,715,489
+2,704,007
+23,550% +$4.15M 0.01% 1060
2025
Q1 		$12.4K Buy
+11,482
New +$13.6K ﹤0.01% 2571
2021
Q3 		– Sell
-84,544
Closed -$938K – 3388
2021
Q2 		$938K Buy
84,544
+32,683
+63% +$319K ﹤0.01% 1850
2021
Q1 		$443K Buy
+51,861
New +$424K ﹤0.01% 1992

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Marshall Wace's SLS Position: Q2 2026 in Review

Marshall Wace sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 2,037,162 shares — an estimated $8.62M sold.

Marshall Wace first reported a position in SLS in Q1 2021 and held it in 7 quarters. The position peaked at $8.62M in Q1 2026. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Marshall Wace reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 2,037,162 SELLAS Life Sciences shares in Q2 2026, an estimated $8.62M.
  • Marshall Wace first reported a position in SELLAS Life Sciences in Q1 2021 and held it in 7 quarters.
  • Marshall Wace's SELLAS Life Sciences position peaked at $8.62M in Q1 2026.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.